MedTrace Logo

A Drug Interaction Study of Cilnidipine and Valsartan

NCT01838967 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2013-10-14

No results posted yet for this study

Summary

The investigators investigate the potential pharmacokinetic drug-drug interaction between Cilnidipine 10 mg and Valsartan 160 mg in healthy male volunteers who receive Cilnidipine 10 mg alone, Valsartan 160 mg , and both together in a 3 period repeatedly.

Conditions

  • Healthy

Interventions

DRUG

C - V - C+V

Drug will be administered to according to C - V - C+V sequence for 3 period.

DRUG

C - C+V - V

Drug will be administered to according to C - C+V - V sequence for 3 period.

DRUG

V - C - C+V

Drug will be administered to according to V - C - C+V sequence for 3 period.

DRUG

V - C+V - C

Drug will be administered to according to V - C+V - C sequence for 3 period.

DRUG

C+V - C - V

Drug will be administered to according to C+V - C - V sequence for 3 period.

DRUG

C+V - V - C

Drug will be administered to according to C+V - V - C sequence for 3 period.

Sponsors & Collaborators

  • IlDong Pharmaceutical Co Ltd

    lead INDUSTRY

Principal Investigators

  • Kyoung Sang You, MD, PhD · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2013-06-30
Completion
2013-10-31

Countries

  • South Korea

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01838967 on ClinicalTrials.gov